Alphonse Ouédraogo, Edith Christiane Bougouma, Nirianne Marie Q Palacpac, Sophie Houard, Issa Nebie, Jean Sawadogo, Gloria D Berges, Issiaka Soulama, Amidou Diarra, Denise Hien, Amidou Z Ouedraogo, Amadou T Konaté, Seni Kouanda, Akira Myoui, Sachiko Ezoe, Ken J Ishii, Takanobu Sato, Flavia D'Alessio, Odile Leroy, Alfred B Tiono, Simon Cousens, Toshihiro Horii, Sodiomon B Sirima
BACKGROUND: BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to aluminium hydroxide gel and reconstituted, prior to administration, with synthetic oligodeoxynucleotides bearing CpG motifs. In healthy Japanese adult males, BK-SE36/CpG was well tolerated. This study assessed its safety and immunogenicity in healthy malaria-exposed African adults and children. METHODS: A double-blind, randomised, controlled, age de-escalating clinical trial was conducted in an urban area of Ouagadougou, Burkina Faso...
2023: Frontiers in Immunology